GlassScriptPhysician profile
Catherine Dillane
NPI 1083029888
$1,776.03
in general payments reported to CMS, 2019-2025
19 companies · $102 in 2025
The $102 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $548 · 2022: $579 · 2023: $367 · 2024: $180 · 2025: $102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $649.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $648.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $564.07 | 2021-2025 | |
| Boston Scientific Corporation | $283.51 | 2021-2024 | Watchman Flx, Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $208.90 | 2021-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $82.54 | 2022 | |
| Esperion Therapeutics, INC. | $69.62 | 2021-2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $68.46 | 2021-2023 | Xarelto |
| Daiichi Sankyo INC. | $63.31 | 2022-2023 | Injectafer |
| Philips North America LLC | $60.35 | 2023-2024 | (5050) Extended Holter |
| Astrazeneca Pharmaceuticals LP | $50.79 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $47.45 | 2023 | Arcalyst |
| Preventice Services, LLC | $47.06 | 2021 | |
| Amgen INC. | $46.32 | 2023-2025 | Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $42.48 | 2021-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $32.31 | 2024 | Arcalyst |
| Merck Sharp & Dohme LLC | $27.71 | 2021-2023 | Verquvo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $26.66 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $24.31 | 2021-2023 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.61 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Dillane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.